Olivo Alicia C 4

What Happened Alicia C. Olivo, EVP, General Counsel & Business Development at Neogenomics (NEO), had derivative awards convert into 29,522 shares in two vesting/conversion events (Feb 21 and Feb 23, 2026). Of those, 11,618 shares were withheld to satisfy tax withholding obligations, resulting in a net increase of 17,904 shares to her beneficial ownership. All reported share prices are $0.00, consistent with conversion/vesting rather than an open-market purchase.

Key Details

• Transaction dates: Feb 21, 2026 (21,079 shares converted; 8,295 shares withheld) and Feb 23, 2026 (8,443 shares converted; 3,323 shares withheld).
• Gross shares acquired by conversion: 29,522; shares withheld for taxes: 11,618; net shares received: 17,904.
• Price per share reported: $0.00 (reflects vesting/conversion, not a cash purchase).
• Transaction codes: M = exercise/conversion of derivative; F = payment of exercise price or tax liability (share withholding).
• Footnote F2 confirms the disposals were withholding of common stock to satisfy tax obligations related to issuance upon release of restricted stock units. Other footnotes list prior option/RSU/PSU grants (2022–2025) that likely produced the vested/converted shares.
• Filing date: Feb 24, 2026 (covering transactions on/through Feb 21–23, 2026).

Context These transactions are routine vesting/conversion events (derivative conversion of RSUs/options) rather than open-market buys or sales. Withholding shares to cover taxes is a common administrative step and does not necessarily signal a change in insider sentiment. For clarity: M = conversion/exercise of a derivative (e.g., vested RSU or exercised option) and F = shares withheld to pay taxes.